Table 5. Baseline characteristics of the study population infected with Omicron by type of treatment.
| Characteristic | TotalN=170 | SotrovimabN=61 | Bamlanivimab/etesevimabN=57 | Casirivimab/imdevimabN=52 |
|---|---|---|---|---|
| Sex (male) – n (%) | 101 (59.41) | 36 (59.02) | 30 (52.63) | 35 (67.31) |
| Age – median (IQR) (range) | 64.5 (14.8) (50–90) | 64.2 (15) (50–90) | 64.8 (14.6) (50–86) | 65.3 (14.8) (50–86) |
| Smoking status – n (%) | ||||
| Smoker | 24 (14.12) | 6 (9.84) | 11 (19.30) | 7 (13.46) |
| Former smoker | 28 (16.47) | 9 (14.75) | 11 (19.30) | 8 (15.38) |
| Non-smoker | 118 (69.41) | 46 (75.41) | 35 (61.40) | 37 (71.15) |
| BMI – n (%) | ||||
| ≤29 | 132 (77.65) | 53 (86.89) | 42 (73.68) | 37 (71.15) |
| ≥30 | 38 (22.35) | 8 (13.11) | 15 (26.32) | 15 (28.85) |
| SARS-CoV-2 serological status – n (%) | ||||
| Antibody-positive | 134 (78.82) | 45 (73.77) | 45 (78.95) | 44 (84.62) |
| Antibody-negative | 35 (20.59) | 16 (26.23) | 11 (19.30) | 8 (15.38) |
| Other | 1 (0.59) | 0 | 1 (1.75) | 0 |
| Anti-SARS-CoV-2 vaccination status – n (%) | ||||
| 3 doses | 62 (36.47) | 24 (39.34) | 19 (33.33) | 19 (36.54) |
| 2 doses ≤120 days | 4 (2.35) | 2 (3.28) | 1 (1.75) | 1 (1.92) |
| 1 or 2 doses ≥120 days | 57 (33.53) | 16 (26.23) | 22 (38.60) | 19 (36.54) |
| Not vaccinated | 42 (24.71) | 18 (29.51) | 13 (22.81) | 11 (21.15) |
| Other | 5 (2.94) | 1 (1.64) | 2 (3.51) | 2 (3.85) |
| Comorbidities – n (%) | ||||
| Diabetes | 6 (3.53) | 2 (3.28) | 2 (3.51) | 2 (3.85) |
| Cardiovascular disease | 61 (35.88) | 18 (29.51) | 17 (29.82) | 26 (50.00) |
| Chronic kidney disease | 9 (5.29) | 4 (6.56) | 2 (3.51) | 3 (5.77) |
| Chronic liver disease | 12 (7.06) | 4 (6.56) | 5 (8.77) | 3 (5.77) |
| Chronic pulmonary disease | 33 (19.41) | 11 (18.03) | 15 (26.32) | 7 (13.46) |
| Immunocompromising conditions | 35 (20.59) | 15 (24.59) | 11 (19.30) | 9 (17.31) |
| Symptoms at enrolment – n (%) | ||||
| Cough | 118 (69.41) | 42 (68.85) | 37 (64.91) | 39 (75.00) |
| Nasal congestion | 69 (40.59) | 28 (45.90) | 25 (43.86) | 16 (30.77) |
| Sore throat | 69 (40.59) | 22 (36.07) | 27 (47.37) | 20 (38.46) |
| Feeling hot or feverish | 99 (58.28) | 37 (60.66) | 32 (56.14) | 30 (57.69) |
| Myalgia | 54 (31.76) | 20 (32.79) | 18 (31.58) | 16 (30.77) |
| Fatigue | 75 (44.12) | 31 (50.82) | 20 (35.09) | 24 (46.15) |
| Headache | 60 (35.29) | 23 (37.70) | 20 (35.09) | 17 (32.69) |
| Anosmia/ageusia | 4 (2.35) | 1 (1.64) | 2 (3.51) | 1 (1.92) |
| Nausea/vomiting | 11 (6.47) | 4 (6.56) | 5 (8.77) | 2 (3.85) |
| Diarrhoea | 12 (7.06) | 5 (8.20) | 4 (7.02) | 3 (5.77) |
| Serum C-reactive protein level – n | 161 | 57 | 56 | 48 |
| Mean (SD), mg/L | 14.29 (21.72) | 12.65 (15.97) | 17.19 (31.07) | 12.87 (12.55) |